OHDSI MEETINGS THIS WEEK
OMOP CDM Oncology WG - Genomic Subgroup Meeting - Tuesday at 9am EThttps://us04web.zoom.us/j/412862164?pwd=NmpEWTdTQlB4N3VxT0tQRXdDWlg0dz09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
OMOP CDM Oncology WG - Leadership Subgroup Meeting - Tuesday at 10am EThttps://us04web.zoom.us/j/988206409?pwd=QzdEZndhelFKSzdKblhubmZvYzkwZz09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
OHDSI Community Call - Tuesday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=96139.930901412523321531221112212141232121131213113112112121536 https://www.ohdsi.org/web/wiki/doku.php?id=projects:ohdsi_community
Pharmacovigilance Evidence Investigation (PEI) - Wednesday at 9am EThttps://meet.lync.com/jnj-its/evoss3/Q7P48H1D https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:kb-wg
Oncology WG - Development Subgroup Meeting - Wednesday at 10am EThttps://www.ohdsi.org/web/wiki/doku.php?id=documentation:oncology:development_schedule https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
OMOP CDM Oncology WG - CDM/Vocabulary Subgroup Meeting - Thursday at 10am EThttps://us04web.zoom.us/j/755053125?pwd=V0dOZVVnY3RMRWgxMVVGTDdVbnA1UT09 https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:oncology-sg
You can find a full list of upcoming OHDSI meetings here: https://docs.google.com/document/d/1X0oa9R-V8cwpF1WQZDJOqcXZguPKRiCZ6XrQ2zXMiuQ/edit
ANNOUNCEMENTS
AMIA Abstract Submissions Due March 11th AMIA’s 2020 Annual Symposium, set to take place Nov 14-18 in Chicago will be accepting abstracts until March 11th. For more information, check out their call for participation:https://www.amia.org/amia2020/call-for-participation
Two OHDSI studies published in Lancet! Another OHDSI study has been published in Lancet! The EHDEN team’s Rheumatology paper is available here: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30075-X/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32317-7/fulltext https://www.ohdsi.org/ohdsi-news-updates/legend-hypertension-study/
We have to talk about liberating minds as well as liberating society
COMMUNITY PUBLICATIONS
Association between Full Electronic Medical Record System Adoption and Drug Use: Antibiotics and Polypharmacy.
YT Park, D Kim, RW Park, K Atalag, IH Kwon, D Yoon and M Choi,
Healthcare informatics research , Jan 2020
We investigated associations between full Electronic Medical Record (EMR) system adoption and drug use in healthcare organizations (HCOs) to explore whether EMR system features such as electronic prescribing, medicines reconciliation, and decision support, might be related to drug use by using the relevant nation-wide data.The study design was cross-sectional. Survey data of the level of adoption of EMR systems were collected for the Organization for Economic Co-operation and Development benchmarking information and communication technologies (ICT) study between November 2013 and January 2014, in Korea. Survey respondents were hospital chief information officers and medical practitioners in primary care clinics. From the national health insurance administrative dataset, two outcomes, the rate of antibiotic prescription and polypharmacy with ≥6 drugs, were extracted.We found that full EMR adoption showed a 16.1% lower antibiotic drug prescription than partial adoption including paper-based medical charts in the hospital only (p = 0.041). Between EMR adoption status and polypharmacy prescription, only those clinics which fully adopted EMR showed significant associations with higher polypharmacy prescriptions (36.9%, p = 0.001).The findings suggested that there might be some confounding effects present and sophisticated ICT may provide some benefits to the quality of care even with some mixed results. Although a negative relationship between full EMR system adoption and antibiotic drug use was only significant in hospitals, EMR system functions searching drugs or listing specific patients might facilitate antibiotic drug use reduction. Positive relationships between full EMR system adoption and polypharmacy rate in general hospitals and clinics, but not hospitals, require further research.
Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.
G Hripcsak, MA Suchard, S Shea, R Chen, SC You, N Pratt, D Madigan, HM Krumholz, PB Ryan and MJ Schuemie,
JAMA internal medicine , Feb 2020 17
Chlorthalidone is currently recommended as the preferred thiazide diuretic to treat hypertension, but no trials have directly compared risks and benefits.To compare the effectiveness and safety of chlorthalidone and hydrochlorothiazide as first-line therapies for hypertension in real-world practice.This is a Large-Scale Evidence Generation and Evaluation in a Network of Databases (LEGEND) observational comparative cohort study with large-scale propensity score stratification and negative-control and synthetic positive-control calibration on databases spanning January 2001 through December 2018. Outpatient and inpatient care episodes of first-time users of antihypertensive monotherapy in the United States based on 2 administrative claims databases and 1 collection of electronic health records were analyzed. Analysis began June 2018.Chlorthalidone and hydrochlorothiazide.The primary outcomes were acute myocardial infarction, hospitalization for heart failure, ischemic or hemorrhagic stroke, and a composite cardiovascular disease outcome including the first 3 outcomes and sudden cardiac death. Fifty-one safety outcomes were measured.Of 730 225 individuals (mean [SD] age, 51.5 [13.3] years; 450 100 women [61.6%]), 36 918 were dispensed or prescribed chlorthalidone and had 149 composite outcome events, and 693 337 were dispensed or prescribed hydrochlorothiazide and had 3089 composite outcome events. No significant difference was found in the associated risk of myocardial infarction, hospitalized heart failure, or stroke, with a calibrated hazard ratio for the composite cardiovascular outcome of 1.00 for chlorthalidone compared with hydrochlorothiazide (95% CI, 0.85-1.17). Chlorthalidone was associated with a significantly higher risk of hypokalemia (hazard ratio [HR], 2.72; 95% CI, 2.38-3.12), hyponatremia (HR, 1.31; 95% CI, 1.16-1.47), acute renal failure (HR, 1.37; 95% CI, 1.15-1.63), chronic kidney disease (HR, 1.24; 95% CI, 1.09-1.42), and type 2 diabetes mellitus (HR, 1.21; 95% CI, 1.12-1.30). Chlorthalidone was associated with a significantly lower risk of diagnosed abnormal weight gain (HR, 0.73; 95% CI, 0.61-0.86).This study found that chlorthalidone use was not associated with significant cardiovascular benefits when compared with hydrochlorothiazide, while its use was associated with greater risk of renal and electrolyte abnormalities. These findings do not support current recommendations to prefer chlorthalidone vs hydrochlorothiazide for hypertension treatment in first-time users was found. We used advanced methods, sensitivity analyses, and diagnostics, but given the possibility of residual confounding and the limited length of observation periods, further study is warranted.
